The Rat Genome Database Pathway Portal by Petri, Victoria et al.
Original article
The Rat Genome Database Pathway Portal
Victoria Petri
1,*, Mary Shimoyama
1, G. Thomas Hayman
1, Jennifer R. Smith
1, Marek Tutaj
1,
Jeff de Pons
1, Melinda R. Dwinell
1,2, Diane H. Munzenmaier
1,2, Simon N. Twigger
1,2, Howard
J. Jacob
1,2 and RGD Team
1
1Human and Molecular Genetics Center and
2Department of Physiology, Medical College of Wisconsin, WI, 53226-3548, USA
*Corresponding author. Tel: 414 456 5788; Fax: 414 456 6516. Email: vpetri@mcw.edu
Submitted 18 January 2011; Revised 3 March 2011; Accepted 17 March 2011
.............................................................................................................................................................................................................................................................................................
The set of interacting molecules collectively referred to as a pathway or network represents a fundamental structural unit,
the building block of the larger, highly integrated networks of biological systems. The scientific community’s interest in
understanding the fine details of how pathways work, communicate with each other and synergize, and how alterations in
one or several pathways may converge into a disease phenotype, places heightened demands on pathway data and
information providers. To meet such demands, the Rat Genome Database [(RGD) http://rgd.mcw.edu] has adopted a multi-
tiered approach to pathway data acquisition and presentation. Resources and tools are continuously added or expanded to
offer more comprehensive pathway data sets as well as enhanced pathway data manipulation, exploration and visualiza-
tion capabilities. At RGD, users can easily identify genes in pathways, see how pathways relate to each other and visualize
pathways in a dynamic and integrated manner. They can access these and other components from several entry points and
effortlessly navigate between them and they can download the data of interest. The Pathway Portal resources at RGD are
presented, and future directions are discussed.
Database URL: http://rgd.mcw.edu
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Introduction
The Rat Genome Database [(RGD) http://rgd.mcw.edu], the
model organism database for the laboratory rat, provides a
breadth of information ranging from genomic and genetic
to molecular and pathway, and to phenotype, disease and
strains [for a description of RGD resources, see Dwinell
et al. (1)]. Important core objects in the database are rep-
resented by rat genes, quantitative trait loci (QTLs) and
strains, among others. RGD also provides information on
human and mouse genes and QTLs to enable the user to
make comparisons between the three mammalian species.
Information on these objects is acquired and stored based
on the manual curation or via automated pipelines using
several controlled vocabularies or ontologies. Tools, de-
veloped internally or developed externally and adjusted
as needed, are used to store, access and mine the data
and navigate between data types (2,3). In order to provide
better, more comprehensive data integration, RGD has
developed several portals which are continuously expanded
both in number and in content. The Pathway Portal project
has been initiated to cover several pathway aspects and
provide a multifaceted resource. The portal offers a range
of pathway data and visualization capabilities and is at the
crossroads of several entry points and other portals such as
the Disease Portals (1). The following sections describe the
various aspects of the pathway portal’s resources including
the annotation of genes to pathway terms and the devel-
opment of the pathway ontology, the building of inter-
active pathway diagrams and the provision of related
navigational capabilities.
Pathway data curation and
ontology development
The functional annotation of rat and, as applicable, of
human and mouse genes, is an important aspect of RGD’s
curation efforts, with several ontologies being used in the
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the best known and widely used biological ontologies (4), is
being used for the annotation of rat genes to molecular
function, biological process and cellular component terms.
A Disease Ontology (DO), based on the C branch of the
Medical Subject Headings [(MeSH) http://www.nlm.nih
.gov/mesh/] from the National Library of Medicine [(NLM)
http://www.nlm.nih.gov/], is used for the annotation of
rat, human and mouse genes to disease terms. The
Mammalian Phenotype Ontology (MP), developed at the
Mouse Genome Informatics (MGI, the Mouse Genome
Database)—http://www.informatics.jax.org/ with RGD con-
tributing terms, is used for the annotation of rat, human
or mouse genes to phenotype terms as applicable. The
Pathway Ontology (PW), developed at RGD and described
in more detail in the following paragraph, is being used
for the annotation of rat, human and mouse genes to
pathway terms.
The goal of PW is to organize the various types of bio-
logical pathways, including disease and altered pathways,
and the relationships between them within a hierarchical
structure. The five major nodes of the ontology are: classic
metabolic, regulatory, signaling, drug and disease path-
ways. External pathways databases and resources such as
the Kyoto Encyclopedia of Genes and Genomes [(KEGG)
http://www.genome.jp/kegg/], PharmGKB (http://www
.pharmgkb.org/index.jsp), Reactome (http://www.reac-
tome.org/) and others along with an extensive research of
the published scientific review literature have been used to
populate the nodes (5–10). Requests for new terms and/or
changes for current ones by the Pathway Interaction
Database [(PID) http://pid.nci.nih.gov/]—a collaborative pro-
ject between the US National Cancer Institute (NCI) and
Nature Publishing Group (NPG; 11) are also contributing
to the expansion and development of the ontology (PID is
using PW to map the human regulatory and signaling path-
ways it manually curates to PW terms to allow users to
browse these pathways by category). Of note is the node
dedicated to disease pathways and the provision of terms
for the altered version(s) of a pathway. While a few path-
way resources outside RGD offer disease pathways, the pro-
vision of altered pathways is a feature unique to the
resources at RGD. An altered pathway is viewed as one
which, due to changes in the functioning of one or several
genes, deviates from the course it would normally have. As
a corollary, a disease pathway is viewed as the sum of
alterations in one or several pathways whose combined
effects result in the inability of the system to adjust to
adverse challenges and is then manifested in the diseased
state. Cancer for instance, is increasingly being viewed as a
disease of altered pathways (12,13).
The RGD’s Pathway Ontology provides a means for the
standardized annotation of genes to any type of biological
pathway; it also serves as a vehicle for linking to and
connecting between ontology reports, pathway diagrams
and suites, disease portals and gene report pages. Pathways
are selected for annotation based on the various roles they
play in the context of the broader systems biology or
physiological networks or in the context of diseases asso-
ciated with a Disease Portal. For instance, insulin secretion
and insulin signaling pathways are essential components of
cellular glucose homeostasis and the impairment of both
has been linked to type 2 diabetes mellitus. Insulin signal-
ing, along with the action of other hormones such as leptin,
is also important for proper energy homeostasis and
disturbances in the control of energy balance have been
associated with obesity and related conditions. Both insulin
and leptin are receptor-activating ligands and rely on trig-
gering downstream signaling pathways to fulfil their roles.
For any pathway targeted for annotation, the review lit-
erature is extensively researched in order to identify the
components of the pathway. Once a set of component
genes has been identified, the rat, human and the mouse
gene complements are annotated to the pathway term.
The rat genes are also functionally annotated to the appro-
priate GO terms based on the rat experimental literature. In
the case of disease and altered pathways, the genes whose
mutations have been implicated in an altered pathway
associated with the condition are annotated to the respect-
ive disease and altered pathway terms, in addition to the
regular pathway and DO terms. Thus, annotations to dis-
ease pathway terms are made for those genes known to be
dysfunctional in the context of an altered pathway. Disease
annotations on a gene-by-gene basis are made using
the DO. If there is an interactive diagram for a particular
disease pathway, a link is provided to the DO Report
page. The report lists all the genes that in some way have
been associated with the condition and have been
annotated to the respective disease term (see ‘Interactive
pathway diagrams and pathway suites’ section). Supporting
references for pathway and functional annotations
are found in the gene report pages (see ‘Pathway data
entry points and navigational capabilities’ section). A copy
of the ontology in OBO format and the annotation files
for the three species are available for download from
the RGD ftp site at ftp://rgd.mcw.edu/pub/data_release/
and ftp://rgd.mcw.edu/pub/data_release/annotated_rgd_
objects_by_ontology/, respectively. The ontology can be
explored on the RGD website at http://rgd.mcw.edu/wg/
pathway?100 or using RGD’s ontology browser (see
‘Pathway data entry points and navigational capabilities’
section below), in the National Center for Biomedical
Ontology’s (NCBO) BioPortal at http://bioportal
.bioontology.org/ontologies/42912 and the European
Bioinformatics Institute’s (EMBL-EBI) Ontology Lookup
Service (OLS) at http://www.ebi.ac.uk/ontology-lookup/
browse.do?ontName=PW.
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pathway suites
The graphical rendition of a pathway is of great interest
as it allows users to instantly see how the interacting part-
ners, their adapters, effectors and regulators mold the
molecular network and define its outcomes. RGD’s inter-
active pathway diagram pages and the more recently
added pathway suites are important components of the
Pathway Portal. The diagrams are built using the Pathway
Studio software package from Ariadne Genomics—http://
www.ariadnegenomics.com/—and the diagram pages are
built within a Content Management System (CMS). The
elements of an interactive pathway diagram page consist
of a description and the diagram of the pathway, a legend
for entities, relationships and shapes, lists of abbreviations
and references, and an import option for users of Ariadne.
Protein domains mentioned in the description link to
their entries in the Pfam database (http://pfam.sanger.ac
.uk/); the description concludes with links to the path-
way ontology report page and as applicable, to related
GO term or DO term ontology report page(s), KEGG map,
PharmGKB report and/or Reactome entry. Every component
in the diagram links to a source of more information:
for instance, protein or protein-related icons link to the
corresponding RGD gene report page or to a dynamic
list of genes, small molecules in the diagram or in a list,
link to the corresponding PubChem (http://www.ncbi.nlm
.nih.gov/pccompound/), Chemical Entities of Biological
Interest [ChEBI (http://www.ebi.ac.uk/chebi/)] or the
Comparative Toxicogenomics Database [CTD (http://ctd
.mdibl.org/)] entry. Accompanying references link to their
PubMed abstracts (http://www.ncbi.nlm.nih.gov/pubmed/).
Very importantly, triggered or otherwise connected path-
ways present in the diagram link to their Ontology Report
pages. Each ontology report contains the GViewer—a tool
displaying the genome-wide view of rat chromosomes indi-
cating the positions of the annotated genes. The report lists
all the genes annotated to the term and shows the path(s)
to the pathway term in the ontology. If there is a diagram
page for that pathway term, its icon is shown on the top of
the report page and it links to the interactive diagram
page. Thus, users can ‘walk’ from one pathway to another,
follow the journey of a signal, navigate between connected
networks and explore their individual features. They can
compare the normal and the altered versions of a pathway,
and examine the role an altered pathway may play in the
development of a disease and how drugs attempt to coun-
teract it. The unique ID of the pathway term, along
with features of the Ariadne and CMS software and bio-
informatics approaches make such pathway expeditions
possible. As an example, the interactive diagram page for
the ‘testosterone biosynthetic pathway’ can be accessed
directly from the list of current diagrams using the
‘Pathways’ entry point of RGD’s home page (Figure 1A
and B); it can also be accessed via the ‘steroid hormone
biosynthetic pathway’, the ‘androgen signaling pathway’
(Figure 2A) or the ‘altered androgen signaling pathway’ dia-
gram pages. The ‘altered androgen signaling pathway’ in
turn, provides links to the normal ‘androgen signaling
pathway’ and the ‘prostate cancer pathway’ (Figure 2B) dia-
gram pages, and to the Cancer Portal while the ‘prostate
cancer pathway’ provides the reciprocal links to the altered
pathway and portal. In addition, the ‘prostate cancer path-
way’ page also provides a link to the DO report page for
Prostatic Neoplasms which lists all the genes that in some
fashion have been associated with the condition or sus-
pected to confer susceptibility and are annotated to the
term. The aforementioned Cancer Portal, one of several
Disease Portals so far released, has targeted breast, uro-
genital and pancreatobiliary neoplasms. Other cancer
types will be targeted in the future. A description of the
Disease Portals project is beyond the scope of this article;
the interested user can check the ’Diseases’ entry point in
the main home page or take a video tour (see ‘Pathway
data entry points and navigational capabilities’ section).
The diagram for the ‘prostate cancer pathway’ has recently
been updated to provide information on miRNAs aber-
rantly expressed in human prostate tumors; each listed
miRNA has a link to its entry in RGD and in the microRNA
database, miRBase (Figure 2B, inset). Announcements on
more important pathway diagram updates as well as
newly published ones can be found in the Latest News sec-
tion and the rotating banner in the main home page
(revisit Figure 1A).
While users can choose the direction or even the length
of their pathway trip, an easy to follow visual overview of
pathways, connected or otherwise related within a larger
network, is provided by the pathway suites. Each suite
offers an instant snapshot of the larger picture that
brings together various types of pathways. It provides a
roadmap of the network that connects several pathways
and as applicable, their altered counterpart(s), disease
and associated drug pathways. This is particularly useful
in cases like diseases, when the global picture is more com-
plex or when users may be less familiar with a topic. For
instance, while most of the currently available diagrams are
covering metabolic, signaling and regulatory pathways and
the newer collection of disease and drug pathways is still
small, the first published suites have addressed networks
involving diseases and drugs. As an example, the prostate
cancer pathway suite (Figure 3) shows the ‘normal’ road
leading from steroid hormone to testosterone biosynthesis
and to subsequent signaling via the androgen receptor and
the ‘defective’ path connecting alteration in androgen sig-
naling to prostate cancer. More recently published suites
deal with the many aspects involved in maintaining the
.............................................................................................................................................................................................................................................................................................
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.............................................................................................................................................................................................................................................................................................Figure 1. Shows a partial view of RGD’s home page with the main entry points, video tutorials, rotating banner and the Latest
News sections, with an arrow pointing to the Pathways entry (A) and the top portion of RGD’s Pathway Resource page the
Pathway entry brings, housing the interactive pathway diagram pages and pathway suites and physiological pathway diagrams
with an arrow pointing to the ‘testosterone biosynthetic pathway’ (B).
.............................................................................................................................................................................................................................................................................................
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cancer pathway’ with the inset showing the list of miRNAs of potential interest in prostate cancer which can be accessed by
clicking on the functional class icon (B).
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user can easily find pertinent pathways from the list of
published diagrams and tailor the trip according to one’s
needs and via the links provided to find answers to ques-
tions such as how is glucose processed or stored, how does
the system respond to changes in its circulating concentra-
tion, whether such responses may falter in type 2 diabetes
and if so, whether drugs are being developed. However,
the less familiar user may find it helpful to peruse the
travel guide offered by the two suites for glucose homeo-
stasis. ‘Glucose Homeostasis Pathway Suite #1: Metabolism
of Glucose and Related Molecules’, as the name suggests,
brings together various pathways of glucose metabolism
such as oxidation and conversion, biosynthesis and storage.
‘Glucose Homeostasis Pathway Suite #2: Glucose
Homeostasis-related Regulation and Signaling’ brings to-
gether insulin secretion and the insulin responsive glucose
transport along with the insulin and glucagon signaling
pathways. The two suites are linked to each other and
from both one can navigate to the Type 2 Diabetes
Pathway Suite and the Diabetes Disease Portal. The two
hypothetical users can thus get to the same basic informa-
tion, albeit following somewhat different routes. Each
pathway suite contains a brief description of what is pre-
sented; icons of the individual pathway diagrams are
grouped by categories as applicable, and are displayed
with the name of the pathway term above and a short de-
scription of the pathway. From the title, the icon or a ‘click
here’ indicator in the short description, the user can link to
the respective pathway diagram page.
A newly developing resource is represented by the
Physiological Pathway Diagrams. This feature is the latest
addition to the portal resources and its goal is to offer a
systems level pathway view (revisit Figure 1B).
Pathway data entry points and
navigational capabilities
Some of the pathway entry points and navigational
capabilities RGD offers have already been mentioned in
the previous sections. The current section will briefly
Figure 3. Shows the Prostate Cancer Pathway Suite.
.............................................................................................................................................................................................................................................................................................
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and how users can navigate between the various kinds of
pathway data and other data types. An obvious entry point
is ‘Pathways’ in the main home page of RGD’s website; it
provides an overview of pathway resources, houses the dy-
namic list of all published interactive pathway diagram
pages and pathway suites, and has links to physiological
pathway pages (Figure 1A and B). ‘Diseases’ entry point in
the main home page provides links to the five Disease
Portals that have been released so far: Diabetes, Obesity/
Metabolic Syndrome, Cancer (breast, urogenital and pan-
creatobiliary), Cardiovascular and Neurological. The disease
portal search options include diseases (default) and asso-
ciated phenotypes, biological processes and pathways; the
results provide lists of annotated objects and links along
with tools. Searches can be narrowed by selecting given
categories and entries within the category. For instance,
in the cancer portal, one can select ‘cell death pathway’
as a pathway category and then choose the ‘intrinsic apop-
toptic pathway’ or one of the extrinsic, death receptor-
mediated pathways. The results show a summary of the
number of rat, human and mouse genes annotated to the
selected term(s), the list of individual genes by species,
the GViewer for the rat genes with the option of viewing
the human or mouse GViewer, or the rat–human or rat–
mouse synteny, and an overview of GO annotations by
vocabulary type. Individual gene reports pages can be
accessed from either the gene list or the GViewer.
Users can search one or several ontologies via the
Ontology Browser or the Genome Viewer accessible from
Data/Ontologies on the home page or from Genome Tools/
GViewer, respectively, and proceed to explore the vocabu-
lary or see the ontology report for a term of interest. As an
example, selecting the pathway ontology in the ontology
browser and typing in ‘glucagon’ will bring up all the terms
in the ontology that contain the word glucagon. Clicking
on the tree icon to the right of a term will show the pos-
ition of that term within the vocabulary and the path(s) to
it; clicking on a term will bring up the ontology report page
for that term. As mentioned, the ontology report shows the
term and its definition, the GViewer for the rat genes, the
list of annotated genes (across the three species), path(s) to
the term and if there is an interactive pathway diagram
available, the icon of the diagram (Figure 4A and B). The
default mode for annotations is term-only; one can switch
to term-and-descendants mode by clicking on the toggle
provided (the arrow in Figure 4A). The GViewer allows
users to add objects to the genome view. For instance,
Figure 4. Shows a partial view of the Ontology Report page for the ‘glucagon signaling pathway’ (A) and the path(s) to the
‘glucagon signaling pathway’ term within the ontology (B).
.............................................................................................................................................................................................................................................................................................
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of the rat genes annotated to the two terms. Users are also
given the option of exporting selected lists of annotated
objects from the GViewer. From within the ontology
report, the user can choose to see the interactive pathway
diagram page, if one exists, to explore the vocabulary or
get to the report page of a gene of interest. The gene
report page contains all the annotations listed by ontolo-
gies along with supporting references and other informa-
tion types and links to orthologous human and mouse gene
report pages and to external sources. Selecting any of the
ontology terms from the annotation list will bring up the
ontology report page for that term.
RatMine [(http://ratmine.mcw.edu/ratmine/begin.do)] is
another tool for finding information on rat genes including
annotations to particular pathway and other ontology
terms via a number of predefined templates or queries.
Results originating from a predefined query or those
arrived at based on the pathway diagrams and ontology
searches can further be analysed. For instance, selected
data sets can be compared for shared or uniquely repre-
sented genes or looked up for term enrichment across sev-
eral ontologies. Additional resources and links allow for
integration of data sets with protein-related analyses and
visualization.
Conclusions and future directions
RGD has adopted a multitiered approach for the acquisi-
tion, dissemination and visualization of pathway data that
includes ontology development and accompanying annota-
tions along with the provision of pathway diagram pages
and related tools. Pathway ‘walks’ mediated by the unique
pathway ontology identifier and global connectivity views
provided by the pathway suites allow users to explore the
range of relationships between various types of pathways
while the individual diagrams offer the picture of the mo-
lecular underpinnings of a particular pathway as presently
understood. The annotation of genes to pathway terms
and, beginning in early 2008 the graphical representation
of pathways, constitute routine curation activities; they also
promote the expansion of the ontology. As mentioned, the
pathway suites are a relatively new feature with the first
being published in 2010. New diagrams and associated an-
notations are released on a regular basis; in the process,
new suites are being built and updates to existing diagrams
are being made. A glimpse of this is captured as entries on
the rotating banner and is briefly summarized in the ‘Latest
News’ section; both are housed on the main home page of
RGD’s website. As of the time of this writing, there are over
9400 pathway annotations in the database and over 75
interactive pathway diagrams have been published. The
pathway resources that RGD offers are of great interest
and are a source of inspiration to the user community as
evidenced by the number of hits they receive and the up-
grades or novel trends exhibited at other places. Ongoing
work will continue to be devoted to increasing the current
collection of diagram pages; future efforts will seek to pro-
vide more comprehensive views of the interconnected and
global networks. This includes the addition of new and
updated pathway suites, updated interactive diagrams as
well as the integration of molecular pathways within the
broader context of physiology and systems biology. A
better coordination between and integration of drug and
disease pathways with the set of pertinent metabolic, regu-
latory or signaling pathways and of altered pathways with
related genomic, genetic and clinical data are being con-
sidered. The development of new and/or the upgrading of
existing tools as the breadth of information expands and
the extent of data integration deepens will continue to
constitute one of RGD’s priorities.
Methods
The Pathway Ontology is being built using the OBO-Edit
software tool developed by the GO Consortium (14). The
pathway diagrams are being built using the Pathway Studio
software tool developed by the Ariadne Genomics group
[http://www.ariadnegenomics.com/]. The package includes
the ResNet mammalian database containing entries for rat,
human and mouse genes, small molecules, processes, dis-
eases and accompanying information. In addition, new
properties can be added in ResNet and values can be as-
signed to these properties. This feature has been exploited
to provide PW IDs for pathways in a diagram as well as links
for lists of genes and for small molecules to their entries in
PubChem, ChEBI or CTD. When a pathway diagram is saved
as an html, a folder with the pathway name is created with
the files for all entities in the diagram and their associated
information in ResNet. The folder is ftp-ed to the RGD’s
website; a script parses the files in the folder for RGD:IDs,
PW:IDs and other links created in ResNet. This allows for
entries in the diagram to link to gene report pages,
dynamic lists of genes, pathway ontology reports or
PubChem, as applicable. The diagram pages are being
built using the WebGUI CMS. A pathway template with
the legend for entities, relationships and shapes, has been
created in the CMS for the pathway diagram pages. Within
the template, articles for the description, the abbreviations
and references, and the Ariadne import option are created
and if applicable, for lists of genes and other objects (e.g.
miRNAs). Lists of genes are being made for members of a
class when there are too many to be displayed on the dia-
gram page or for target genes. An HTTP Proxy utility is used
to bring in and display the diagram in the page. Links
such as those to ontology report pages or entries at vari-
ous pathway resources and links to PubMed and Pfam
databases are created within the CMS.
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